Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs
Alyson Haslam, Jennifer Gill, Vinay Prasad
Abstract
This cross-sectional study estimates the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs.
Topics & Concepts
MedicineFood and drug administrationCancerDrugOncologyCancer drugsPostmarketing surveillanceInternal medicineImmune systemPharmacologyAdverse effectImmunologyCancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology ResearchEconomic and Financial Impacts of Cancer